Document is current
Any future updates will be listed below
-
Authors
Lin, Wenxue https://orcid.org/0000-0002-8245-9063
Krebs, Nicolle M.
Zhu, Junjia https://orcid.org/0000-0003-1311-3752
Horn, Kimberly
Foulds, Jonathan https://orcid.org/0000-0003-2296-0726
Evins, A. Eden
Muscat, Joshua E.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (P50DA036107)
Center for Tobacco Products (P50DA036107-05S1)
- License Information
-
More Information
Article History
Received: 26 February 2024
Revised: 20 August 2024
Accepted: 25 August 2024
First Online: 4 September 2024
Declarations
:
: The study was approved by the Massachusetts General Hospital, George Washington University and Penn State College of Medicine Institutional Review Boards.
: Informed consent was obtained from all individual participants included in the study.
: Jonathan Foulds has completed paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer (not related to reduced nicotine cigarettes). Other authors have no relevant financial or non-financial interests to disclose.
